Systemic lupus erythematosus after alpha-Interferon therapy for chronic hepatitis C: a case report and review of the literature

2000 ◽  
Vol 95 (1) ◽  
pp. 310-312 ◽  
Author(s):  
Satoru Fukuyama ◽  
Eiji Kajiwara ◽  
Norihisa Suzuki ◽  
Naoki Miyazaki ◽  
Seizoh Sadoshima ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Chronic Hepatitis ◽  
Case Report ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Lupus Erythematosus ◽  
Interferon Therapy ◽  
Alpha Interferon ◽  
Review Of The Literature ◽  
Systemic Lupus

Treatment of chronic hepatitis C in a patient with systemic lupus erythematosus

2004 ◽  
Vol 28 (12) ◽  
pp. 1297
Author(s):  
Jean-Marie Péron ◽  
Laurent Zabraniechki ◽  
François Pey ◽  
Christophe Bureau ◽  
Séverine Valmary ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Lupus Erythematosus ◽  
Systemic Lupus

scholarly journals AB1276 NON-INTERFERON THERAPY OF CHRONIC HEPATITIS C IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND SECONDARY SJÖGREN SYNDROME - CASE REPORT

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1929.2-1929
Author(s):  
I. Menshikova ◽  
Y. Pak ◽  
A. Rybaulina
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Lupus Erythematosus ◽  
Sjögren Syndrome ◽  
Sjogren Syndrome ◽  
Systemic Lupus

Background:Hepatitis C virus infection is one of the most significant public health problems in the world. To date, the problem of selection of therapy is very relevant for patients with autoimmune diseases and chronic hepatitis C [1]. Patients with systemic lupus erythematosus (SLE) are forced to take different doses of steroids, often in combination with immunosuppressants (mycophenolate mofetil, azathioprine, etc.) even in the case of long-term remission. Such therapy for many years can contribute to the reactivation of hepatitis C.Objectives:To describe a clinical case of the effectiveness of the combined use of interferon-free therapy and therapy of steroids in a patient with SLE, secondary Sjogren syndrome and chronic hepatitis C.Methods:56 years-old woman was admitted to the rheumatology department of Clinical Hospital No. 1 in December 2018 with the debut of SLE: photosensitivity, aphthous stomatitis, arthritis, pleurisy, sicca syndrome, leukopenia, ANA 1: 2560, antibodies to dsDNA 55.95 IU / ml, positive antiSS-A (Ro). At the same time, it became known that she was infected with hepatitis C virus in 1985 presumably. At the time of hospitalization, anti-HCV was positive, the virus genotype was 1b, the activity of the process was low (HCV RNA 6.6x104, AST 33 U/L and ALT 25 U/L). The patient was prescribed corticosteroids (methylprednisolone 16 mg/day) and hydroxychloroquine 400 mg/day. In January 2019, after gastroenterologist, hematologist and infectious disease specialist advise, it was decided to conduct the patient a specific interferon-free antiviral therapy for chronic hepatitis C (a 24-week course with asunaprevir and daclatasvir), given the potential long-term glucocorticoid therapy, with the prospect of treating the patient with cytotoxic drugs, and the possibility of reactivation of chronic hepatitis C amid of immunosuppressive therapy for SLE and Sjogren syndrome.Results:Low-disease activity of SLE was achieved in a month, and after 24-week course of antiviral therapy, there was no increase in SLE activity, and positive laboratory and clinical dynamics were noted.Conclusion:Thus, the use of interferon-free therapy of chronic hepatitis C in patients with systemic lupus erythematosus and secondary Sjogren syndrome shows possible ways to safe treatment of this disease in patients with diffuse connective tissue diseases.References:[1]Xiaobo Zhu, Mingqi Wang, Mei Liu, Xinghao Yu & Peng Huang. Efficacy and safety of direct-acting antivirals for treatment-naive patients with genotype 1 hepatitis C virus infection. Per Med. October 2019. 16 (5): 421 doi: 10.2217/pme-2018-0121.Acknowledgments:Supported by the “Russian Academic Excellence Project 5-100”Disclosure of Interests:None declared

scholarly journals Anti-MDA5 Antibody Dermatomyositis Overlap with Systemic Lupus Erythematosus: A Case Report and Review of the Literature

2016 ◽  
Vol 10 (1) ◽  
pp. 122-128 ◽  
Author(s):  
Emily C. Milam ◽  
Jacobo Futran ◽  
Andrew G. Franks Jr.
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Case Report ◽  
Interstitial Lung Disease ◽  
Connective Tissue ◽  
Lupus Erythematosus ◽  
Clinical Phenotype ◽  
Review Of The Literature ◽  
Systemic Lupus ◽  
American College Of Rheumatology ◽  
Clinical Presentations

Background: Dermatomyositis (DM) is an autoimmune connective tissue disease that primarily targets the muscle, skin, and lungs. Many patients have autoantibodies that correspond to distinct clinical phenotypes. Melanoma differentiation-associated gene 5 (anti-MDA5) antibody, a specific antibody that targets the melanoma differentiation-associated gene 5 (MDA5), has been reported in DM cases and is significant for a distinct cutaneous presentation and rapidly progressive interstitial lung disease. Objective: Herein, we describe a patient with DM with a positive anti-MDA5 antibody and characteristic clinical phenotype, who subsequently developed coexisting systemic lupus erythematosus (SLE). A diagnosis of SLE was supported by his clinical phenotype, positive serologies, hypocomplementemia, and progression to glomerulonephritis and lupus cerebritis, features of which fulfilled the American College of Rheumatology criteria for SLE. Conclusion: DM is known to overlap with other autoimmune diseases, including SLE, and coexistence can lead to a wide variety of clinical presentations. SLE overlapping with anti-MDA5 positive DM may present with distinct clinical features.

Sign in / Sign up

Export Citation Format

Share Document